Sun, Aug 31, 2014, 6:23 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cytomedix, Inc. Message Board

  • lettucecometogether lettucecometogether Oct 10, 2013 10:30 AM Flag

    Looks like Jorden being investigated at OPXA. Need this lawfirm to swing on over to CMXI

    Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Opexa Therapeutics, Inc. (“Opexa” or the “Company”) (OPXA) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for the Company’s Amended and Restated 2010 Stock Incentive Plan.
    Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on October 3, 2013, the Board of Directors recommends that Opexa’s shareholders vote to approve an amendment to the Company’s Amended and Restated 2010 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 3,000,000 shares. The issuance of the additional shares could have a substantial dilutive effect on the shares of Opexa common stock.

 
CMXI
0.355-0.014(-3.79%)Aug 29 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.